Outcomes for early-relapsing patients with lenalidomide
| Drug . | ORR overall . | ORR POD24 . | CR overall . | CR POD24 . | PFS overall . | PFS POD24 . | OS overall . | OS POD24 . |
|---|---|---|---|---|---|---|---|---|
| R2 (Augment)1 | 80% | 80% | 35% | 30% | 39.4 mo | 30.4 mo | 95% (2 y) | ≈90% (2 y) |
| R2 (Magnify)30 | 72% | 65% | 42% | 32% | NR (median) | 27.4 mo (median) | N/A | N/A |
| O-Len31 | 79.1% | 70.8% | 46.5% | N/A | 64.7% (2 y) | 62.5% (2 y) | 86.9% (2 y) | 82.8% (2 y) |
| Drug . | ORR overall . | ORR POD24 . | CR overall . | CR POD24 . | PFS overall . | PFS POD24 . | OS overall . | OS POD24 . |
|---|---|---|---|---|---|---|---|---|
| R2 (Augment)1 | 80% | 80% | 35% | 30% | 39.4 mo | 30.4 mo | 95% (2 y) | ≈90% (2 y) |
| R2 (Magnify)30 | 72% | 65% | 42% | 32% | NR (median) | 27.4 mo (median) | N/A | N/A |
| O-Len31 | 79.1% | 70.8% | 46.5% | N/A | 64.7% (2 y) | 62.5% (2 y) | 86.9% (2 y) | 82.8% (2 y) |
N/A, not available; NR, not reached.